Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

Abstract

There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless legs syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS.

Description

field of invention The present invention relates to adenosine A 2a Use of receptor antagonists for the treatment of a variety of neurological syndromes involving the extrapyramidal motor system (ie, extrapyramidal syndromes) that occur after short-term and long-term use of almost all antipsychotic drugs. The present invention also relates to adenosine A 2a Use of receptor antagonists for the treatment of other abnormal movement disorders such as restless legs syndrome (RLS) and periodic limb movements during sleep (PLMS). Background of the invention Extrapyramidal syndrome (EPS) is a collective term for a series of adverse neurologic effects associated with the use of antipsychotic drugs. There are six distinct classes of EPS-associated neurological syndromes, four of which - dystonia, akathisia, pseudoparkinsonism (parkinsonism) and tardive dyskinesia - in patients receiving antipsychotic medication Especially prevalent among patients. Dystonia is painful spasm of muscl...

AI Technical Summary

Problems solved by technology

EPS is more common with typical antipsychotics but has also been reported with atypical agents

Images